#weight-loss-drugs

#weight-loss-drugs

Medicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.

Ozempic's explosive sales growth reflects its successful transition from a diabetes treatment to a leading weight loss drug.

Zepbound leads to more weight loss than Wegovy in clinical trials.

Genetic test MyPhenome can predict response to weight-loss drug semaglutide with 75% accuracy, categorizing people into four types of weight gain.

The rising popularity of Ozempic alternatives continues despite expected supply increases due to significant pricing differences.

FDA's crackdown on cheap weight-loss drugs threatens access for many Americans, raising treatment costs.

Compounded versions of Wegovy and Zepbound to be phased out as shortages are declared over.

Governments may use weight-loss drugs as a cop-out instead of implementing hard policy choices to tackle obesity.

The soaring prices of weight-loss drugs in the US lead to significant consumer challenges compared to prices in other countries.

The scientists behind GLP-1 based weight-loss drugs Ozempic and Wegovy received a $3 million Breakthrough Prize for their life-saving contributions.

Demand for Ozempic and its alternatives has led to compounded versions, but brand manufacturers are actively trying to eliminate this competition.

Elon Musk's use of an anti-obesity drug signals a shift towards mainstream acceptance and discussion of weight-loss medications.

Pharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.

Medicare is likely to negotiate lower prices for Ozempic and Wegovy starting in 2027.

Ozempic, originally a diabetes treatment, has become a major weight loss drug, generating $14 billion in 2023 sales for Novo Nordisk.

Eli Lilly launches Zepbound vials at lower prices to address supply shortages and boost access for patients.

Eli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.

Eli Lilly's new Zepbound vials improve drug access and affordability despite increased user difficulty compared to autoinjector pens.

Eli Lilly's Zepbound missed sales estimates, raising concerns over the demand for popular weight loss drugs.

Emerging obesity treatments like orforglipron and retatrutide show significant potential, possibly transforming the landscape of weight loss drugs in 2025.

Teenagers are increasingly being prescribed semaglutide drugs, raising concerns about long-term health impacts.

Verdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.

Weight-loss drugs are reshaping the conversation around obesity, challenging moral stigmas and impacting societal attitudes toward health and personal responsibility.

Powerful weight-loss drugs are increasing patient engagement and diagnoses of obesity-related conditions in the U.S. healthcare system.

Weight-loss drugs like Ozempic and Wegovy are a start, but solving obesity requires addressing underlying food system issues.

Weight-loss drugs can improve heart health and reduce the risk of mental illness, but they also have risks, including increased joint pain and pancreatitis.

GLP-1 receptor agonists may reduce cravings not just for food but also for drugs and alcohol, aiding recovery from addiction.

Blue Cross Blue Shield of Michigan has limited coverage for weight-loss drugs, impacting thousands who rely on them for health and well-being.

Biden administration proposed allowing Medicare to cover anti-obesity medications to improve long-term health and reduce future costs.

CBO predicts Medicare's anti-obesity drug coverage would lead to significant net costs for taxpayers.

Roche's weight loss drug CT-388 shows high vomiting rates in trials, raising concerns for investors.

CagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.

Patients are struggling to obtain weight-loss and diabetes medications due to supply issues and insurance problems, turning instead to cheaper online alternatives.

FDA warns about safety issues with compounded weight-loss drugs as pharmaceutical companies fight against them amid legal battles and differing interests.

Consumers overdosing on knock-off semaglutide weight-loss drugs.

Weight-loss drugs like semaglutide may significantly enhance longevity and health by reducing overall mortality rates.

Weight-loss drugs like Wegovy and Zepbound, based on GLP-1, have broader applications beyond weight loss and diabetes.

The rise in demand for weight-loss drugs has led consumers to purchase potentially dangerous gray market alternatives online.